USMCA's 2026 Joint Review: Incentives Over Tariffs?

As global pharmaceutical supply chains continue to evolve, governments are placing greater emphasis on regional manufacturing resilience rather than relying solely on international sourcing. The upcoming 2026 USMCA Joint Review has sparked discussions around strengthening pharmaceutical production across the United States, Canada, and Mexico through coordinated industrial policies.

Rather than introducing additional tariffs, policy recommendations emphasize regional investment incentives to expand the production of Active Pharmaceutical Ingredients (APIs) and essential generic medicines. This approach aims to improve supply security, encourage domestic manufacturing, and reduce dependence on overseas suppliers while supporting long-term economic competitiveness.

For pharmaceutical manufacturers, procurement professionals, and healthcare suppliers, these proposals could influence sourcing strategies across North America in the years ahead.

Why Regional Manufacturing Matters

Recent supply chain disruptions have highlighted the importance of diversified and geographically balanced pharmaceutical production.

Regional manufacturing offers several advantages:

• Improved supply chain resilience

• Reduced transportation risks

• Shorter delivery times

• Stronger regional collaboration

• Better regulatory coordination

• Increased production flexibility

Expanding pharmaceutical manufacturing within North America can help improve access to critical medicines during periods of global disruption.

Regional pharmaceutical manufacturing also depends on the reliable supply of essential raw materials such as Propylene Glycol (USP Grade), Polyethylene Glycol (PEG), Mannitol, Citric Acid, Sorbitol, Glycerin, and Isopropyl Alcohol (IPA). Expanding North American production could increase regional demand for these widely used pharmaceutical ingredients while improving supply chain resilience.

Incentives Instead of Tariffs

Rather than relying primarily on import tariffs, policymakers are considering investment-focused strategies to encourage pharmaceutical manufacturing.

Potential measures include:

• Manufacturing tax incentives

• Investment support programs

• API production incentives

• Infrastructure development

• Research and innovation funding

• Workforce development initiatives

These policies aim to strengthen regional competitiveness while supporting long-term pharmaceutical supply chain security.

Procurement Considerations

Pharmaceutical procurement teams should monitor regional policy developments and evaluate their sourcing strategies accordingly.

Key considerations include:

• Supplier diversification

• Regional sourcing opportunities

• Regulatory compliance

• Long-term supply agreements

• Manufacturing capacity expansion

• Business continuity planning

Companies that maintain flexible supplier networks across multiple regions are generally better positioned to adapt to changing market conditions.

Looking Ahead

The 2026 USMCA Joint Review highlights a broader trend toward regionalizing critical pharmaceutical manufacturing. While global sourcing will continue to play an important role, increased investment in North American API and generic drug production could create new procurement opportunities and improve long-term supply resilience.

For procurement professionals, balancing global supplier relationships with emerging regional manufacturing capabilities will remain an important strategy for managing future supply chain risks.

Key Takeaways

• The 2026 USMCA Joint Review emphasizes regional pharmaceutical manufacturing.

• Investment incentives may play a larger role than tariffs in strengthening supply chains.

• North American API and generic drug production could expand over time.

• Procurement teams should monitor policy developments and regional manufacturing investments.

• Diversified sourcing strategies remain essential for long-term supply chain resilience.